

Serial No. 09/600,659, filed July 20, 2000
Docket No. 1103326-0629
Page 4 of 18

Please amend the application as follows:


In the claims:

This listing of claims will replace all prior versions,
and listings, of claims in the application.

1. (canceled)

2. (currently amended) A formulation comprising:

(i) an inhibitor of carboxypeptidase U or a pharmaceutically acceptable salt thereof; and
(ii) a thrombin inhibitor or an ester or prodrug derivative thereof, or a salt and/or solvate of any of these, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier, wherein the inhibitor of carboxypeptidase U is a compound of formula I



or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt,
wherein:

R₁ is selected from the group consisting of:

~~C₄-C₆ alkyl, substituted with one or more basic groups,~~
cycloalkyl, substituted with one or more basic groups;
heterocyclyl, comprising at least one nitrogen atom, and substituted with one or more basic groups;

Serial No. 09/600,659, filed July 20, 2000

Docket No. 1103326-0629

Page 5 of 18

heterocyclyl, comprising at least one hetero atom selected from S or O, and substituted with one or more basic groups; and

aryl, substituted with one or more basic groups;

R₂ is selected from the group consisting of H, acyl, acylamino, alkyl, alkylcarbamoyl, alkylthio, alkoxy, aroyl, aroylamino, aryloxy, arylthio, amidino, amino, aryl, carbamoyl, carboxy, cyano, cycloalkyl, formyl, guanidino, halogen, heterocyclyl, hydroxy, nitro, thiol, a

Z₂N-CO-O- group, a ZO-CO-NZ- group, and a Z₂N-CO-NZ- group;

R₃ is selected from the group consisting of COOR₅, SO(OR₅), SO₃R₅, P=O(OR₅)₂, B(OR₅)₂, P-OR₅(OR₅), tetrazole, and a carboxylic acid isostere;

R₄ is SH, S-CO-C₁-C₆ alkyl, or S-CO-aryl;

R₅ is H, C₁-C₆ alkyl, or aryl;

R₆ is H or C₁-C₆ alkyl;

X is selected from the group consisting of O, S, SO, SO₂, C(Z)₂, N(Z), NR₆SO₂, and SO₂NR₆;

Y is C(Z)₂; and

Z is independently selected from the group consisting of H, C₁-C₆ alkyl, aryl, cycloalkyl and heterocyclyl.

3. (withdrawn) A formulation comprising:

(i) an inhibitor of carboxypeptidase U or a pharmaceutically acceptable salt thereof; and


(ii) a thrombin inhibitor or a derivative thereof,

in admixture with a pharmaceutically acceptable adjuvant,

diluent, or carrier, wherein the inhibitor of carboxypeptidase U

Serial No. 09/600,659, filed July 20, 2000
 Docket No. 1103326-0629
 Page 6 of 18

is a compound of formula II,




or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, wherein:

R₇ is selected from the group consisting of:

C₁-C₆ alkyl, substituted with one or more basic groups;
 cycloalkyl, substituted with one or more basic groups;
 heterocyclyl, comprising at least one nitrogen atom, and substituted with one or more basic groups;
 heterocyclyl, comprising at least one hetero atom selected from S or O, and substituted with one or more basic groups; and
 aryl, substituted with one or more basic groups;

R₈ is selected from the group consisting of H, acyl, acylamino, alkyl, alkylcarbamoyl, alkylthio, alkoxy, aroyl, aroylamino, aryloxy, arylthio, amidino, amino, aryl, carbamoyl, carboxy, cyano, cycloalkyl, formyl, guanidino, halogen, heterocyclyl, hydroxy, nitro, thiol, Z₂N-CO-O-, ZO-CO-NZ-, and Z₂N-CO-NZ-;

R₉ is selected from the group consisting of COOR₁₁, SO(OR₁₁), SO₂OR₁₁, P=O(OR₁₁)₂, B(OR₁₁)₂, P=OR₁₁(OR₁₁), tetrazole, and a carboxylic acid isostere;



Serial No. 09/600,659, filed July 20, 2000
Docket No. 1103326-0629
Page 7 of 18

R₁₁ is H, C₁-C₆ alkyl, or aryl;

R₁₂ is C₁-C₆ alkyl, aryl, cycloalkyl, heterocyclyl, or an optionally N-substituted

H₂N-C(Z)-CONH-C(Z)- or H₂N-C(Z)- group;

R₁₃ is H or C₁-C₆ alkyl;

X is selected from the group consisting of O, S, SO, SO₂, C(Z)₂, N(Z), NR₁₃SO₂, SO₂NR₁₃, NR₁₃CO, and CONR₁₃;

Y is selected from the group consisting of O, N(Z), S, C(Z)₂, and a single bond; and

Z is independently selected from the group consisting of H, C₁-C₆ alkyl, aryl, cycloalkyl, and heterocyclyl, with the proviso that when X is O, S, SO, SO₂, N(Z), NR₇SO₂, SO₂NR₇, or NR₇CO, then Y is C(Z)₂ or a single bond.

4. (currently amended) The formulation according to claim 2 ~~or 3~~, wherein the thrombin inhibitor is a low molecular weight thrombin inhibitor.

5. (previously presented) The formulation according to claim 4, wherein the low molecular weight thrombin inhibitor is a peptide-based, amino acid-based, and/or peptide analogue-based, thrombin inhibitor with one to four peptide linkages.

6. (previously presented) The formulation according to claim 5, wherein the low molecular weight thrombin inhibitor is HOOC-CH₂-(R)Cgl-Aze-Pab-H or a prodrug thereof.

7. (previously presented) The formulation according to claim 6, wherein the prodrug is EtOOC-CH₂-(R)Cgl-Aze-Pab-OH.

Serial No. 09/600,659, filed July 20, 2000
Docket No. 1103326-0629
Page 8 of 18

8. (currently amended) The formulation according to claim 2 ~~ex~~
~~3~~, wherein the molar ratio between the inhibitor of
carboxypeptidase U and the thrombin inhibitor lies in the range
of from ~~about~~ 1000:1 to ~~about~~ 1:1000.

9. (currently amended) A kit of parts comprising:

(i) a vessel comprising an inhibitor of carboxypeptidase U, or a
pharmaceutically acceptable salt thereof;

(ii) a vessel comprising a thrombin inhibitor, or an ester or
prodrug derivative thereof, or a salt and/or solvate of any of
these; and

(iii) instructions for the sequential, separate or simultaneous
administration of the inhibitors (i) and (ii) to a patient in
need thereof, wherein the inhibitor of carboxypeptidase U is a
compound according to claim 2 ~~ex-3~~.

10. (canceled)

11. (withdrawn) The kit of parts according to claim 9, wherein
the thrombin inhibitor is a low molecular weight thrombin
inhibitor.

12. (withdrawn) The kit of parts according to claim 11, wherein
the low molecular weight thrombin inhibitor is a peptide-based,
amino acid-based, and/or peptide analogue-based, thrombin
inhibitor with one to four peptide linkages.

13. (withdrawn) The kit of parts according to claim 12, wherein
the low molecular weight thrombin inhibitor is HOOC-CH₂-(R)Cgl-
Aze-Pab-H or a prodrug thereof.

Serial No. 09/600,659, filed July 20, 2000
Docket No. 1103326-0629
Page 9 of 18

14. (withdrawn) The kit of parts according to claim 13, wherein the prodrug is $\text{EtOOC-CH}_2\text{-(R)Cgl-Aze-Pab-OH}$.

15. (currently amended) The kit of parts according to claim 9, wherein the molar ratio between the inhibitor of carboxypeptidase U and the thrombin inhibitor lies in the range of from ~~about~~ 1000:1 to ~~about~~ 1:1000.

16. (currently amended) A kit of parts comprising:

(i) a formulation comprising an inhibitor of carboxypeptidase U, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier; and
(ii) a formulation comprising a thrombin inhibitor, or an ester or prodrug derivative thereof, or a salt and/or solvate of any of these, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier,
wherein inhibitors (i) and (ii) are each formulated for administration in conjunction with the other, and wherein the inhibitor of carboxypeptidase U is a compound according to claim 2 ~~or~~ 3.

17. (withdrawn) The kit of parts according to claim 16, wherein inhibitors (i) and (ii) are formulated for sequential, separate or simultaneous administration.

18. (canceled)

Serial No. 09/600,659, filed July 20, 2000
Docket No. 1103326-0629
Page 10 of 18

19. (withdrawn) The kit of parts according to claim 16, wherein the thrombin inhibitor is a low molecular weight thrombin inhibitor.

20. (withdrawn) The kit of parts according to claim 19, wherein the low molecular weight thrombin inhibitor is a peptide-based, amino acid-based, and/or peptide analogue-based, thrombin inhibitor with one to four peptide linkages.

21. (withdrawn) The kit of parts according to claim 20, wherein the low molecular weight thrombin inhibitor is $\text{HOOC-CH}_2\text{-(R)Cgl-Aze-Pab-H}$ or a prodrug thereof.

22. (withdrawn) The kit of parts according to claim 21, wherein the prodrug is $\text{EtOOC-CH}_2\text{-(R)Cgl-Aze-Pab-OH}$.

23. (currently amended) The kit of parts according to claim 16, wherein the molar ratio between the inhibitor of carboxypeptidase U and the thrombin inhibitor lies in the range of from ~~about~~ 1000:1 to ~~about~~ 1:1000.

24. (canceled)

25. (currently amended) A method for the treatment of ~~a patient suffering from, or susceptible to, a condition in which inhibition of thrombin and/or inhibition of carboxypeptidase U are required or desired~~ thrombosis and/or hypercoagulability, which method comprises administering to ~~the~~ a patient in need thereof a therapeutically effective total amount of:

Serial No. 09/600,659, filed July 20, 2000
Docket No. 1103326-0629
Page 11 of 18

(i) an inhibitor of carboxypeptidase U, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and
(ii) a thrombin inhibitor, or an ester or prodrug derivative thereof, or a salt and/or solvate of any of these, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier, wherein the inhibitor of carboxypeptidase U is a compound according to claim 2 ~~ex-3~~.

26. (withdrawn) The method according to claim 25, wherein the administration of inhibitors (i) and (ii) is sequential, separate or simultaneous.

27. (canceled)

28. (withdrawn) The method according to claim 25, wherein the thrombin inhibitor is a low molecular weight thrombin inhibitor.

29. (withdrawn) The method according to claim 28, wherein the low molecular weight thrombin inhibitor is a peptide-based, amino acid-based, and/or peptide analogue-based, thrombin inhibitor with one to four peptide linkages.

30. (withdrawn) The method according to claim 29, wherein the low molecular weight thrombin inhibitor is $\text{HOOC-CH}_2\text{-(R)Cgl-Aze-Pab-H}$ or a prodrug thereof.

31. (withdrawn) The method according to claim 30, wherein the prodrug is $\text{EtOOC-CH}_2\text{-(R)Cgl-Aze-Pab-OH}$.

Serial No. 09/600,659, filed July 20, 2000
Docket No. 1103326-0629
Page 12 of 18

32. (currently amended) The method according to claim 25, wherein the molar ratio between the inhibitor of carboxypeptidase U and the thrombin inhibitor lies in the range of from ~~about~~ 1000:1 to ~~about~~ 1:1000.

33. (currently amended) A method for treatment of a ~~patient suffering from, or susceptible to, a condition in which inhibition of thrombin and/or inhibition of carboxypeptidase U are required or desired~~ thrombosis and/or hypercoagulability, which method comprises administering to ~~the~~ a patient in need thereof a formulation according to claim 2 ~~or 3~~.

34-40. (canceled)

41. (currently amended) The formulation according to claim 2 ~~or 3~~, wherein the basic group is selected from the group consisting of amino, amidino, and guanidino.

42. (currently amended) The formulation according to claim 2 ~~or 3~~, wherein the molar ratio between the inhibitor of carboxypeptidase U and the thrombin inhibitor lies in the range of from ~~about~~ 50:1 to ~~about~~ 1:50.

43-46. (canceled)

47. (currently amended) The kit of parts according to claim 9, wherein the molar ratio between the inhibitor of carboxypeptidase U and the thrombin inhibitor lies in the range from ~~about~~ 50:1 to 1:50.

48-53. (canceled)

Serial No. 09/600,659, filed July 20, 2000
Docket No. 1103326-0629
Page 13 of 18

54. (currently amended) The kit of parts according to claim 16, wherein the molar ratio between the inhibitor of carboxypeptidase U and the thrombin inhibitor lies in the range of from ~~about~~ 50:1 to ~~about~~ 1:50.

55-60. (canceled)

61. (currently amended) The method according to claim 25, wherein the molar ratio between the inhibitor of carboxypeptidase U and the thrombin inhibitor lies in the range of from ~~about~~ 50:1 to ~~about~~ 1:50.

62. (canceled)

63. (canceled)

64. (new) A method for reducing the risk of thrombosis and/or hypercoagulability, which method comprises administering to a patient a therapeutically effective total amount of:

(i) an inhibitor of carboxypeptidase U, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier; and

(ii) a thrombin inhibitor, or an ester or prodrug thereof, or a salt and/or solvate of any of these, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier, wherein the inhibitor of carboxypeptidase U is a compound according to claim 2.